SCHEMBL10003875

SCHEMBL10003875

CCOC(=O)c1nc2c(OC(C)C)c(C(=O)OCc3ccccc3)n(C)c2nc1CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GABRA2 P47869 3/20 0.39
▸ GABRB2 P47870 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ SLC5A1 P13866 1/20 0.37
▸ SLC5A2 P31639 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ MAOB P27338 2/20 0.36
▸ ADORA2A P29274 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003357 0.85 ALDH1A1 (0.45) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10004170 0.85 USP2 (0.37) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10003034 0.80 HTT (0.44) ALDH1A1KMT2AKDM4EHPGDADORA3
SCHEMBL10003428 0.78 POLB (0.35) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10004195 0.78 KMT2A (0.36) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10003360 0.77 CYP1A2 (0.47) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10003794 0.76 GABRA2 (0.45) ALDH1A1GABRA2GABRB2MAPTLMNA
SCHEMBL10003388 0.76 GABRA2 (0.45) ALDH1A1KMT2AGABRA2GABRB2KDM4E
SCHEMBL10003981 0.75 MAPK1 (0.38) ALDH1A1GABRA2GABRB2KDM4EHPGD
SCHEMBL10004160 0.74 ALDH1A1 (0.42) ALDH1A1KMT2AGABRA2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885KMT2A 423/4885GABRA2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback